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Abstract
Purpose: Myocardial late gadolinium enhancement was originally validated using higher than label-recommended
doses of gadolinium chelate. The objective of this study was to evaluate available evidence for various gadolinium
dosing regimens used for CMR. The relationship of gadolinium dose warnings (due to nephrogenic systemic
fibrosis) announced in 2008 to gadolinium dosing regimens was also examined.
Methods: We conducted a meta-analysis of peer reviewed publications from January, 2004 to December, 2010.
Major subject search headings (MeSh) terms from the National Library of Medicine’s PubMed were: contrast media,
gadolinium, heart, magnetic resonance imaging; searches were limited to human studies with abstracts published
in English. Case reports, review articles, editorials, MRA related papers and all reports that did not indicate
gadolinium type or weight-based dose were excluded. For all included references, full text was available to
determine the total administered gadolinium dose on a per kg basis. Average and median dose values were
weighted by the number of subjects in each study.
Results: 399 publications were identified in PubMed; 233 studies matched the inclusion criteria, encompassing
19,934 patients with mean age 54.2 ± 11.4 (range 9.3 to 76 years). 34 trials were related to perfusion testing and
199 to myocardial late gadolinium enhancement. In 2004, the weighted-median and weighted-mean contrast dose
were 0.15 and 0.16 ± 0.06 mmol/kg, respectively. Median contrast doses for 2005-2010 were: 0.2 mmol/kg for all
years, respectively. Mean contrast doses for the years 2005-2010 were: 0.19 ± 0.03, 0.18 ± 0.04, 0.18 ± 0.10, 0.18 ±
0.03, 0.18 ± 0.04 and 0.18 ± 0.04 mmol/kg, respectively (p for trend, NS). Gadopentetate dimeglumine was the
most frequent gadolinium type [114 (48.9%) studies]. No change in mean gadolinium dose was present before,
versus after the Food and Drug Administration (FDA) black box warning (p > 0.05). Three multi-center dose
ranging trials have been published for cardiac MRI applications.
Conclusion: CMR studies in the peer-reviewed published literature routinely use higher gadolinium doses than
regulatory agencies indicated in the package leaflet. Clinical trials should be supported to determine the
appropriate doses of gadolinium for CMR studies.
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Cardiovascular Magnetic Resonance (CMR) is a highly
reproducible modality able to assess myocardial tissue
characteristics and myocardial perfusion [1,2]. The most
common gadolinium (Gd) enhanced techniques for
CMR are detection of myocardial scar [3,4] using late
gadolinium enhancement (LGE) methods and detection
of myocardial ischemia using stress/rest perfusion CMR
[5-7].
CMR provides outstanding characterization of myo-
cardial size and function, but LGE is a unique capability
of CMR compared to other imaging modalities. LGE
CMR was originally validated using higher than label-
recommended doses of gadolinium (Gd) chelate
[3,8-10], i.e., 0.2 mmol/kg of a conventional gadolinium
chelate.
In 2006, the association between nephrogenic systemic
fibrosis (NSF) and exposure to Gd-based contrast agents
(GBCAs) was reported [11]. Although multiple different
associations with NSF and GBCA have been reported,
the most important are renal failure and dialysis [12,13].
In late 2007, the United States Food and Drug Adminis-
tration (FDA) issued a black box warning regarding
GBCAs due to its association to NSF [14]. European
regulators also issued warnings at the same time. All
GBCAs had revised label warnings in early 2008. Cen-
ters performing magnetic resonance imaging (MRI)
instituted policies to identify patients at high risk for
NSF [13], including advanced age (> 60 yrs), eGFR < 30
mL/min/1.73 m
2, dialysis and acute renal failure. The
success of a screening policy for NSF was recently
demonstrated, further suggesting that renal failure and
high dose gadolinium administration may be the pri-
mary underlying risk factors for NSF development [15].
Recently in 2010, the FDA further recommended that
label doses of GBCA’s (generally 0.1 mmol/kg for “con-
ventional” GBCAs) not be exceeded in any patient.
Currently, gadolinium enhanced MRI of the heart is
off-label use for all FDA approved GBCAs. The purpose
of this is to evaluate evidence-based dosing regimens for
GBCAs for CMR. In particular, we describe CMR dosing
regimens used before and after the FDA black box
warnings that were instituted in 2008.
Methods
We conducted a meta-analysis on MEDLINE of peer
reviewed publications from January, 2004 to December,
2010. Full text was evaluated for all matching references
to determine the total administered gadolinium dose.
The publications were examined for potentially dupli-
cate or overlapping data. Corresponding investigators
were contacted for clarification when data were unclear
or inadequate. QUOSA Information Manger Version 8.0
(QUOSA Inc., Waltham, MA, USA) was used to search
and retrieve full text publications using appropriate
major subject search headings (MeSh) terms from the
National Library of Medicine’s PubMed abstract collec-
tion. The MeSh terms were: contrast media, gadolinium,
heart, magnetic resonance imaging. Searches were lim-
ited to human studies with abstracts published in Eng-
lish from January 1, 2004 to December 3, 2010.
Peer-reviewed publications were included in the analy-
sis if: 1) stress/rest perfusion or LGE were performed of
the myocardium; 2) the number and age of study parti-
cipants were reported; 3) gadolinium dose was reported
on a per kilogram (kg) basis. Studies that described only
phantoms or animals were excluded. Case reports,
review articles, editorials, and magnetic resonance angio-
graphy (including coronary angiography) studies were
excluded. Full text was available for all studies. Studies
that evaluated both perfusion and LGE were classified
as LGE studies. For those studies, the total GBCA dose
was used for analysis.
Statistical analysis
Categorical variables are presented as numbers and per-
centages. Median and mean values were weighted
according to the number of subjects in each study. The
main analysis was performed at the patient level, and
the secondary analysis was performed at the contrast
media level. Two-sample two tailed t-test was used to
determine significant differences between two sets of
results. P-values < 0.05 were considered to be statisti-
cally significant.
Results
PubMed searches identified 399 potentially relevant
publications. Table 1 summarizes the Current FDA
approved GBCAs. One hundred sixty-six studies were
excluded. The exclusion causes are summarized in
Table 2. Two hundred thirty-three studies matched the
inclusion criteria encompassing 19,934 patients with
mean age 54.2 ± 11.4 (range 9.3 to 76 years) in the
peer-reviewed literature published between 2004 and
2010. The majority of the patients (11,793, 59.2% were
between 41 and 60 years of age. Four hundred seventeen
(2%) patients were less than 20 years old, 1,565 (7.9%)
patients were between 21 and 40 years, and 6,158
(30.9%) of patients were older than 60 years. The litera-
ture selection process is summarized in Figure 1.
Study and population characteristics are summarized
in Table 3. Thirty-four trials were classified as perfusion
evaluation and 199 were myocardial LGE evaluation.
The most common clinical applications were myocardial
infarction and viability testing (n = 88; 37.7%) followed
by cardiomyopathy (n = 76; 32.6%) studies (Table 4).
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tions. The main focus of the publication was related to
pre and post-surgery of congenital heart disease in 8
studies (3.4%). In 2004, the weighted-median and -mean
reported contrast dose was 0.15 and 0.16 ± 0.06 mmol/
kg, respectively. Median contrast doses for 2005-2010
were: 0.2 mmol/kg for all years, respectively. Mean con-
trast doses for the years 2005-2010 were: 0.19 ± 0.03,
0.18 ± 0.04, 0.18 ± 0.10, 0.18 ± 0.03, 0.18 ± 0.04 and
0.18 ± 0.04 mmol/kg, respectively (p for trend, not sig-
nificant). No change in mean gadolinium dose was pre-
sent before, versus after the FDA black box warning (p
> 0.05) (Figure 2).
Over all years, 4678 participants received gadolinium
in perfusion protocols. For perfusion, the weighted-med-
ian and -mean contrast doses were 0.2 and 0.17 ± 0.05
mmol/Kg, respectively. Also, 15,256 participants were
studied in LGE protocols. For LGE MRI, the weighted-
Table 1 Current FDA approved GBCAs
Contrast agent Trade name Manufacture Label dose Age FDA Approved
indication
Gadopentetate Dimeglumine (Gd-
DTPA2)
Magnevist
® Bayer
Healthcare
0.1 mmol/Kg (0.2 mL/Kg) 2 years and older Central Nervous
System*
Extracranial/Extraspinal
Tissues**
Body (excluding the
heart)***
Gadodiamide (Gd-DTPA-BMA) Omniscan
® GE Healthcare 0.1 mmol/Kg (0.2 mL/Kg)
0.05 mmol/Kg (0.1 mL/Kg)§
2-16 years and
adults
Central Nervous
System*
Body [noncardiac]****
Gadoversetamide (Gd-DTPA-
BMEA)
OptiMark
® Mallinckrodt 0.1 mmol/Kg (0.2 mL/Kg) 18 to 76 years Central Nervous
System*
Liver
Gadoteridol ProHance
® Bracco
Diagnostics
0.1 mmol/Kg (0.2 mL/Kg)
Additional dose of 0.2 mmol/Kg (0.4
mL/Kg) §§§
2 - 18 years and
adults
Central Nervous
System*
Extracranial/Extraspinal
Tissues**
Gadobenate Dimeglumine (Gd-
BOPTA)
MultiHance
® Bracco
Diagnostics
0.1 mmol/Kg (0.2 mL/Kg) 2 years and older Central Nervous
System*
Gadobutrol (Gd-DO3A-butrol) Gadavist
®
Gadovist
®;§§
Bayer
Healthcare
0.1 mmol/Kg (0.1 mL/Kg) 2 years and older Disrupted Blood Brain
Barrier
Central Nervous
System*
Gadofosveset trisodium Ablavar
®
Vasovist
®§§
Lantheus
Medcl
0.03 mmol/Kg (0.12 mL/Kg) Adults Aortoiliac occlusive
disease
Gadoxetate disodium Eovist
®
Primovist
®§§
Bayer
Healthcare
0.025 mmol/Kg (0.1 mL/Kg) Adults Liver Lesions
Outside the US only, shown for
completeness
Gadoterate Meglumine (Gd-HP-
DOTA)
Dotarem
®
Artirem
®§§
Guerbet 0.1 mmol/Kg (0.2 mL/Kg) 2 years and older Central Nervous System*
Body [noncardiac]****
Other agents previously approved but not currently available are Mangafodipir Trisodium (Teslascan
®; GE Healthcare) and Ferumoxides (Feridex
®; Amag Pharms).
NDA, New Drug Application. * Abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. ** Abnormal vascularity in the head and neck.
*** Abnormal vascularity in the body. **** Intrathoracic, abdominal, pelvic cavities, and the retroperitoneal space. § For Kidney studies. §§ Only for use outside
the United States. §§§ May be given up to 30 minutes after the first dose for patients with normal renal function suspected of having poorly enhancing central
Nervous System lesions.
Table 2 Reasons for exclusion of publications
2004 2005 2006 2007 2008 2009 2010 Total
Phantom or animal model 0 (0) 2 (8) 5 (20) 4 (21) 5 (15.6) 6 (17.7) 4 (21) 26 (15.7)
No weight-based contrast dose 2 (16.7) 9 (36) 5 (20) 3 (15.8) 6 (18.7) 8 (23.5) 1 (5.2) 34 (20.4)
Case reports 3 (25) 3 (12) 5 (20) 3 (15.8) 7 (21.9) 8 (23.5) 5 (26.4) 34 (20.4)
Review articles 1 (8.3) 2 (8) 2 (8) 5 (26.4) 7 (21.9) 6 (17.7) 4 (21) 27 (16.3)
Editorials 4 (33.3) 5 (20) 4 (16) 0 (0) 0 (0) 2 (5.8) 0 (0) 15 (9.1)
MRA 2 (16.7) 4 (16) 4 (16) 4 (21) 7 (21.9) 4 (11.8) 5 (26.4) 30 (18.1)
Total 12 (100) 25 (100) 25 (100) 19 (100) 32 (100) 34 (100) 19 (100) 166 (100)
MRA, magnetic resonance angiography. Data is presented as number and percentages.
Nacif et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:18
http://www.jcmr-online.com/content/14/1/18
Page 3 of 8median and -mean contrast doses were 0.2 and 0.18 ±
0.04 mmol/Kg (p < 0.001 compared to mean dose for
perfusion studies).
From 2004 to 2010, Gadopentetate dimeglumine
(Magnevist
®) was used most frequently (n = 114; 48.9%
of the publications) followed by Gadodiamide (Omnis-
can
®) (n = 39; 16.7%) and Gadoterate meglumine
(Dotarem
®) (n = 15; 6.5%). Gadoterate meglumine is
not currently available in the United States. A large
percentage of trials reported incomplete or inconsistent
data regarding type and dose of GBCAs, (23.1% of all
studies). Table 5 summarizes those findings.
Table 6 shows multicenter phase II/III CMR studies
that have been performed for assessment of GBCA
dose. One study evaluated gadolinium dose for LGE
(566 patients). The other ones (99 and 94 patients,
respectively) evaluated GBCA dose for myocardial
perfusion.
Figure 1 Flow diagram of review identification and selection of patients include meta-analysis.
Table 3 Characteristics of publications included in the meta-analysis
Year Studies Participants Age (years) Perfusion
studies
LGE
studies
Median GBCA dose (mmol/Kg)* Mean GBCA dose (mmol/Kg)*
2004 22 (9.5) 697 (3.5) 56.1 ± 8.7 6 (17.6) 16 (8.1) 0.15 0.16 ± 0.06
2005 19 (8.2) 2,123 (10.7) 54.4 ± 8.4 2 (5.9) 17 (8.6) 0.2 0.19 ± 0.03
2006 26 (11.1) 4,366 (22.0) 54.9 ± 11.3 5 (14.8) 21 (10.5) 0.2 0.18 ± 0.04
2007 31 (13.3) 1,123 (5.6) 46.1 ± 16.9 3 (8.9) 28 (14.1) 0.2 0.18 ± 0.10
2008 40 (17.1) 2,264 (11.3) 55 ± 8.9 7 (20.5) 33 (16.5) 0.2 0.18 ± 0.03
2009 45 (19.3) 3,965 (19.9) 56.2 ± 10.3 5 (14.7) 40 (20.1) 0.2 0.18 ± 0.04
2010 50 (21.5) 5,396 (27.0) 55 ± 11.3 6 (17.6) 44 (22.1) 0.2 0.18 ± 0.04
Total 233 (100) 19,934 (100) 54.2 ± 11.4 34 (100) 199 (100) 0.2 0.18 ± 0.04
Median, Mean and standard deviations or number and percentages as appropriate. LGE, late gadolinium enhancement.
Studies that had both LGE and perfusion results were categorized as LGE. For these studies, total gadolinium dose is shown.
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Given the recent attention to the potential adverse
effects of high dose gadolinium MRI studies, we evalu-
ated the current status of GBCA use for CMR as pre-
sented in the peer-reviewed literature, emphasizing
trends before and after nephrogenic fibrosis guidelines
were issued in 2008. This meta-analysis showed that the
median GBCA dose for English peer reviewed publica-
tions for CMR (19,934 patients) was 0.2 mmol/kg.
Further, no change in mean or median gadolinium dose
was present before, versus after the FDA issued GBCA
black box warnings (p > 0.05). To date, only 1 multi-
center, dose ranging trial has been conducted for a sin-
gle gadolinium contrast agent (gadoversetaminde) for
LGE [16]. For perfusion CMR, two dose ranging multi-
center trials for gadopentetate dimeglumine have been
published in the literature, with “optimal” gadolinium
dose ranging from 0.05 to 0.15 mmol/kg [17,18], The
gadolinium dose reported in the literature for perfusion
CMR varies between 0.1-0.2. (Table 6) [16-18]. It
remains to be seen if future CMR studies will incorpo-
rate and report lower gadolinium doses.
CMR is widely available and has been validated at 0.2
mmol/Kg for detection of scar [3,4] and at a range of
doses for myocardial ischemia using stress/rest perfusion
protocol [5-7]. The most frequent topics in the peer-
reviewed literature focused on myocardial infarction
[19,20] and viability [21,22], cardiomyopathy [23-25],
ischemia [26,27], and myocarditis [28]. It seems quite
clear that these published, investigational studies have
routinely used higher doses of GBCAs than FDA label-
ing. A limitation of this report is that we are unable to
determine if the pattern of GBCA use with CMR in
published studies reflects the broader routine clinical
pattern of practice for GBCA use.
Patients with cardiovascular disease must be screened
for risk factors that are associated with NSF. In addition
to the major risk factor of renal failure, an additional
risk factor for NSF might to be multiple/high dose gado-
linium enhanced MRI examinations. In particular, Adu-
judeh et al [29-31], Perez et al [15] and others have
shown that patients who receive higher cumulative
doses of gadopentetate dimeglumine have a higher risk
Table 4 Topics of CMR studies that used GBCAs in peer reviewed publications
2004 2005 2006 2007 2008 2009 2010 Total
Myocardial infarction 6 (27.2) 3 (15.8) 9 (34.6) 5 (16.1) 5 (12.5) 17 (3.7) 16 (32) 61 (26.1)
Others cardiomyopathies* 1 (4.6) 6 (31.5) 4 (15.4) 10 (32.2) 11 (27.5) 10 (22.3) 10 (20) 52 (22.3)
Ischemia 6 (27.2) 2 (10.5) 5 (19.2) 3 (9.6) 7 (17.5) 5 (11.2) 6 (12) 34 (14.5)
Myocardial viability 5 (22.7) 3 (15.8) 2 (7.6) 1 (3.3) 6 (15) 4 (8.9) 6 (12) 27 (11.6)
Hypertrophic Cardiomyopathy 2 (9.1) 4 (21.1) 1 (3.9) 2 (6.5) 5 (12.5) 3 (6.6) 7 (14) 24 (10.3)
Myocarditis 1 (4.6) 0 (0) 0 (0) 1 (3.3) 0 (0) 0 (0) 0 (0) 2 (1.0)
Pulmonary Hypertension 1 (4.6) 1 (5.3) 0 (0) 1 (3.3) 0 (0) 2 (4.3) 0 (0) 5 (2.1)
Valvular disease 0 (0) 0 (0) 2 (7.7) 0 (0) 1 (2.5) 1 (2.3) 1 (2) 5 (2.1)
Cardiac mass 0 (0) 0 (0) 1 (3.9) 3 (9.6) 1 (2.5) 0 (0) 0 (0) 5 (2.1)
Others 0 (0) 0 (0) 2 (7.7) 5 (16.1) 4 (10) 3 (6.7) 4 (8) 18 (7.9)
Total 22 (100) 19 (100) 26 (100) 31 (100) 40 (100) 45 (100) 50 (100) 233 (100)
Data is presented as number and percentages. * Heart Failure, Post-Surgery status, Deposit disease, ARVD, Atrial Fibrilation, Congenital Heart disease, Tokotsubo
Figure 2 (A) Weighted mean contrast dose (mmol/Kg) from
2004 to 2010.( B) No change in mean gadolinium contrast dose
before versus after FDA black box warning. Dashed horizontal lines
represents minimum contrast dose and horizontal lines represents
maximum contrast dose.
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lower doses. Patients who have cardiovascular disease
may have other medical conditions that require MRI
examination. Thus, the relatively high dose of GBCA
used for CMR studies may be particularly relevant for
patients who may also undergo non-cardiovascular MRI.
The accepted approach to determination of the mini-
mally effective GBCA dose is evaluation in multi-center
phase II and III studies. For LGE, only one contrast
agent (gadoversetamide) has been subject to a combined
phase II/III evaluation. That study concluded that a
gadolinium dose of 0.2 mmol/kg gadoversetamide was
appropriate for LGE CMR. For myocardial perfusion,
Wolff et al indicated that the appropriate dose for a sin-
gle perfusion evaluation was 0.05 mmol/kg with gado-
pentetate dimeglumine [17]. Giang et al showed that
gadolinium doses of 0.10 or 0.15 of gadopentetate dime-
glumine were optimal for perfusion CMR. Since that
time however, considerable advances have been made in
both hardware and software.
Approximately 23% of peer-reviewed publications
regarding gadolinium enhanced CMR had incomplete or
inaccurate information related to GBCAs. “Gadolinium
DTPA,” a nonspecific description of the specific contrast
agent, was frequently described as the type of contrast
media that was administered. In order to maintain
patient safety, it is essential that gadolinium contrast
agents be accurately reported in the medical record.
Contrast agents for MRI are currently treated the same
as all other hospital medications by the United States
Joint Commission on Accreditation of Healthcare Orga-
nizations. These standards require accurate recording
and reconciliation of the type, route and dose of admin-
istration. The American College of Radiology standards
for the practice of MRI also indicates that radiology
reports should record type, route and dose of gadoli-
nium administration. With the advent of NSF, it is likely
that improved reporting of gadolinium type may take
place in the future.
Dose and efficacy studies for GBCAs focused on CMR
have rarely been performed. One factor is likely the high
cost of multi-center trials which is typically borne by the
drug manufacturer. Thus, peer-reviewed literature and
individual physician experience from single-site experi-
ence will probably continue to guide clinical practice. In
principle, the lowest drug dose that is diagnostically effi-
cacious is recommended by regulatory authorities. With-
out well-controlled clinical trials, the lowest gadolinium
dose that is efficacious is essentially unknown for most
of the available CMR contrast agents. Recently, there
have been attempts to use lower gadolinium dose in
large multi-center studies, such as EuroCMR (gadoli-
nium dose < 0.16 mmol/kg) [32]. In addition, the Multi-
Ethnic Study of Atherosclerosis (MESA)[33] protocol for
LGE CMR involving approximately 3000 study partici-
pants requires a gadolinium dose of 0.15 mmol/kg; a
higher dose of 0.2 mmol/kg was not recommended by
the MESA renal working group due to safety concerns
in an elderly, volunteer population (D. Bluemke, J Lima,
personal communication).
Table 5 Use of gadolinium contrast agents for CMR studies in peer reviewed publications
Contrast agent Publications (percent) by year
2004 2005 2006 2007 2008 2009 2010 Total
Gadopentetate Dimeglumine 13 (59) 10 (52.6) 11 (42.3) 15 (48.3) 24 (60) 25 (55.5) 16 (32) 114 (48.9)
Gadodiamide 4 (18.2) 4 (21) 5 (19.2) 8 (25.8) 4 (10) 5 (11.1) 9 (18) 39 (16.7)
Gadoterate Meglumine 0 (0) 0 (0) 2 (7.7) 4 (13) 0 (0) 5 (11.1) 4 (8) 15 (6.5)
Gadobutrol 0 (0) 0 (0) 0 (0) 0 (0) 3 (7.5) 0 (0) 2 (4) 5 (2.2)
Gadobenate Dimeglumine 0 (0) 0 (0) 0 (0) 1 (3.2) 1 (2.5) 1 (2.3) 1 (2) 4 (1.8)
Gadoversetamide 0 (0) 0 (0) 1 (3.8) 0 (0) 1 (2.5) 0 (0) 0 (0) 2 (0.8)
Not specified 5 (22.8) 5 (26.4) 7 (27) 3 (9.7) 7 (17.5) 9 (20) 18 (36) 54 (23.1)
Total 22 (100) 19 (100) 26 (100) 31 (100) 40 (100) 45 (100) 50 (100) 233 (100)
Data is presented as number and percentages
Table 6 Prior Multi-Center Phase II/III studies on GBCAs for CMR indications
Investigators Number of study
subjects
Year Journal Protocol Contrast agent mmol/kg Recommended gadolinium
dose
Wolff et al
[17]
99 2004 Circulation Perfusion Gadopentetate
Dimeglumine
0.05; 0.10; 0.15 0.05 mmol/kg
Giang et al
[18]
94 2004 Eur Heart
J
Perfusion Gadopentetate
Dimeglumine
0.05; 0.10; 0.15 0.10 or 0.15 mmol/Kg
Kim et al [16] 566 2008 Circulation LGE Gadoversetamide 0.5, 0.1, 0.2 or
0.3
0.2 mmol/kg
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administration for CMR publications needs immediate
attention in the peer reviewed literature. We strongly
recommend that authors, editors and reviewers of peer-
reviewed journals demand standardization of GBCA
reporting in the literature. Professional societies that are
particularly concerned about the use of CMR, such as
the Society of Cardiovascular Magnetic Resonance
(SCMR) and the International Society for Magnetic
Resonance in Medicine (ISMRM), could provide educa-
tion and guidelines for practice in this regard. For CMR,
it is important to report not only the weight based dose
of the GBCA (mmol/kg or ml/Kg) and the chemical
name and manufacturer, but also the delay time for
imaging. Generic statements such as “gadolinium
DTPA” should be avoided.
There are several limitations of this study. We limited
our search to articles with abstracts and those published
in English with specific MeSh terms from PubMed.
Thus, our review probably does not reflect the world-
wide use of gadolinium contrast agents. In addition, the
FDA black box warning in 2007 was issued by a United
States agency. We hypothesized that CMR publications
appearing after 2008 were likely to be influenced by this
warning. However, warnings about gadolinium use were
slightly different in Europe although they were also
issued about this same time. In addition, FDA-approved
GBCA medication label changes took place only in early
2008. It is possible that changes in gadolinium dose
policies in research studies may take longer to appear in
the literature than our inclusion literature date of
December, 2010. The observation of discernable trend
in dose reduction for CMR over this period might be a
reflection of changing referral patterns for CMR:
patients with renal failure are no longer being referred
for GBCA studies and there is less consideration for low
dose by CMR physicians in a somewhat healthier
population.
In conclusion, we report that CMR studies in the
peer-reviewed published literature routinely use higher
gadolinium doses than FDA label indicated dose. Clini-
cal trials should be supported to determine the appro-
priate doses of gadolinium enhancement of the
myocardium.
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